drugset / Trial / NCT07229144
OM336 in Seropositive Autoimmune Diseases
NaSequentialOpen-labelTreatment
Summary
An early-phase clinical trial evaluating the safety, tolerability, and pharmacokinetics of OM336 in adult participants with seropositive autoimmune diseases. OM336 is administered subcutaneously in ascending dose cohorts.
Timeline
- Start
- 2025-10-01
- Primary completion
- 2027-06
- Completion
- 2028-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | OM336 | Unknown | — | Subcutaneous |